Clinical Trial

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-11.
Status change: Not Yet Recruiting → Recruiting 2024-05-27
Trial Details
NCT Number NCT05868395
Lead Sponsor Medical University of Vienna
Conditions Mantle-cell Lymphoma
Enrollment 16 participants
Start Date 2024-01-02
Primary Completion 2027-05-24 (estimated)
Study Completion 2027-05-24 (estimated)
Updated on ClinicalTrials.gov 2024-05-29